Research & Development

Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.

The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.

After failing in a Phase II trial in social anxiety disorder, Bionomics thinks mid-stage data for BNC210 in post-traumatic stress disorder may now position the drug as a novel therapy for PTSD.

The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.

CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Deal Snapshot: The companies had announced the deal back in February 2021, but citing its “strategic focus,” AbbVie told Caribou it was backing out.

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.

The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.

The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.

The announcement that LEAP-006 and LEAP-008, both in non-small cell lung cancer, did not meet their primary endpoints adds to a string of failures for the combination.